scholarly journals Synergistic effect of targeting dishevelled‑3 and the epidermal growth factor receptor‑tyrosine kinase inhibitor on mesothelioma cells in vitro

2017 ◽  
Author(s):  
Gaku Moriyama ◽  
Maya Tanigawa ◽  
Kosuke Sakai ◽  
Yusuke Hirata ◽  
Satoshi Kikuchi ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Synergistic Effect ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Epidermal Growth

scholarly journals Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance

Oncotarget ◽  
2018 ◽  
Vol 9 (20) ◽  
pp. 15418-15434 ◽  
Author(s):  
Carina Heydt ◽  
Sebastian Michels ◽  
Kenneth S. Thress ◽  
Sven Bergner ◽  
Jürgen Wolf ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Epidermal Growth ◽  
Novel Approaches ◽  
Inhibitor Resistance

scholarly journals Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma

RSC Advances ◽  
2018 ◽  
Vol 8 (70) ◽  
pp. 40387-40394 ◽  
Author(s):  
Mohamed W. Attwa ◽  
Adnan A. Kadi ◽  
Hany W. Darwish ◽  
Ali S. Abdelhameed
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Third Generation ◽  
Epidermal Growth ◽  
Egfr Tki

Olmutinib (OTB, Olita™) is an orally available third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).

Sign in / Sign up

Export Citation Format

Share Document